Wells Fargo & Company lowered shares of NeuroPace (NASDAQ:NPCE – Free Report) from an overweight rating to an equal weight rating in a report published on Friday morning, Marketbeat Ratings reports. Wells Fargo & Company currently has $9.00 target price on the stock.
NPCE has been the subject of a number of other research reports. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of NeuroPace in a research note on Wednesday, July 29th. JPMorgan Chase & Co. cut shares of NeuroPace from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $20.00 to $9.00 in a research report on Friday. Raymond James Financial set a $21.00 price objective on shares of NeuroPace in a research report on Tuesday, September 15th. Weiss Ratings downgraded shares of NeuroPace from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, October 2nd. Finally, Leerink Partners lowered shares of NeuroPace from an “outperform” rating to a “market perform” rating and set a $7.00 target price for the company. in a research report on Friday. Five investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $15.50.
Check Out Our Latest Report on NPCE
NeuroPace Price Performance
Hedge Funds Weigh In On NeuroPace
Large investors have recently added to or reduced their stakes in the business. Legal & General Group Plc bought a new position in shares of NeuroPace during the second quarter valued at about $41,000. Algert Global LLC grew its stake in shares of NeuroPace by 2.9% in the second quarter. Algert Global LLC now owns 184,774 shares of the company’s stock worth $2,936,000 after purchasing an additional 5,218 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of NeuroPace in the second quarter worth about $157,000. Lazard Asset Management LLC increased its holdings in NeuroPace by 9.8% during the 1st quarter. Lazard Asset Management LLC now owns 124,305 shares of the company’s stock valued at $1,635,000 after purchasing an additional 11,078 shares during the period. Finally, Diversified Trust Co purchased a new position in NeuroPace during the 3rd quarter valued at about $153,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.
Key NeuroPace News
Here’s some of the latest news about NPCE:
- Positive Sentiment: NeuroPace reported a Q3 loss of $0.03 per share, improved from a $0.11 loss a year earlier and better than analyst estimates. Zacks Q3 earnings report
- Negative Sentiment: The company cut its 2026 revenue outlook to $91–$92 million, well below the roughly $100.4 million consensus estimate, reinforcing concerns about its sales trajectory. Revenue miss and lowered outlook
- Negative Sentiment: Analyst actions added pressure: JPMorgan cut its rating to neutral and lowered its target from $20 to $9; Wells Fargo and Leerink Partners also downgraded the shares. KeyCorp maintained an overweight rating but cut its target from $18 to $14. Analyst rating changes
NeuroPace Company Profile
NeuroPace, Inc. is a medical technology company focused on treating people with drug-resistant epilepsy. Its primary product is the RNS System, an implanted responsive neurostimulation device designed to detect patterns of abnormal electrical activity in the brain and deliver stimulation in response. The RNS System includes a neurostimulator implanted in the skull and leads placed in or near seizure-onset areas of the brain. Clinicians use the system to review brain activity and adjust treatment, while patients can use accompanying tools to record information about their seizures and share it with their care team.
See Also
- Five stocks we like better than NeuroPace
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.
